Efficacy of alogliptin, a dipeptidyl peptidase‐4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) – receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Issue 8 (November 2013)

• Record Type: Journal Article
• Authors: Sakata, Koji; Hayakawa, Manabu; Yano, Yuichiro; Tamaki, Noboru; Yokota, Naoto; Eto, Takuma; Watanabe, Reiko; Hirayama, Naoteru; Matsuo, Takeshi; Kuroki, Kazuo; Sagara, Seiji; Mishima, Osamu; Koga, Masahiro; Nagata, Naoto; Nishino, Yuri; Kitamura, Kazuo; Kario, Kazuomi; Takeuchi, Masayoshi; Yamagishi, Sho‐ichi
• Is Part Of: Diabetes/metabolism research and reviews. Volume 29:Issue 8(2013:Nov.)
• Page Start: 624
• Page End: 630
• Publication Date: 2013-11
• Subjects: Diabetes -- Periodicals; Metabolism -- Periodicals; 616.642
• DOI: 10.1002/dmrr.2437
• Languages: English
• ISSNs: 1520-7552

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="dmrr2437-sec-0001" sec-type="section"> <title>Background</title> <p>To examine the effects of alogliptin, a dipeptidyl peptidase‐4 inhibitor, on glucose parameters, the advanced glycation end product (AGE)‐receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes patients.</p> </sec> <sec id="dmrr2437-sec-0002" sec-type="section"> <title>Methods</title> <p>Sixty‐one patients whose HbA<sub>lc</sub> ≥ 6.1% (mean age 64.7 years; 67% men; mean HbA<sub>lc</sub> 7.4%; 57% were pharmacologically treated) underwent blood and urine sampling and analysis before and after 12 weeks of treatment with alogliptin (25 mg once daily).</p> </sec> <sec id="dmrr2437-sec-0003" sec-type="section"> <title>Results</title> <p>Alogliptin treatment significantly reduced fasting glucose (160.3 mg/dL at baseline versus 138.0 mg/dL at 12 weeks), glycoalbumin (21.1% at baseline versus 18.9% at 12 weeks), HbAlc (7.4% at baseline versus 6.9% at 12 weeks), circulating soluble form of RAGE concentrations (847.3 pg/mL at baseline versus 791.4 pg/mL at 12 weeks) and urine albumin to creatinine ratio (31.6 mg/g Cr at baseline versus 26.5 mg/g Cr at 12 weeks), whereas 1, 5‐anhydroglucitol concentrations were significantly increased (7.5 µg/mL at baseline versus 11.6 µg/mL at 12 weeks; all <italic>P</italic> <underline><</underline> 0.05). Circulating AGEs concentrations were reduced only in patients with baseline AGEs ≥7 U/mL (<italic>n</italic> = 33, from 8.2 U/mL to 7.2U /mL; <italic>p</italic> < 0.01) after alogliptin treatment. The treatment‐induced change of soluble form of sRAGE concentrations was associated with changes of 1, 5‐anhydroglucitol and HbA<sub>lc</sub> concentrations (<italic>rho</italic> = −0.32 and 0.29, respectively). Meanwhile, the treatment‐induced change of urine albumin to creatinine ratio was associated with a change in the fasting glucose concentration (<italic>rho</italic> = 0.25; all <italic>p</italic> < 0.05). During the intervention, alogliptin treatment was well tolerated without any hypoglycemia or side effects.</p> </sec> <sec id="dmrr2437-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Alogliptin treatment improved the AGE–RAGE axis and reduced albuminuria in Japanese type 2 diabetes patients. Copyright © 2013 John Wiley & Sons, Ltd.</p> </sec> </abstract>